These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 17763685

  • 1. [Clinical features and treatment history of clarithromycin resistance in M. avium-intracellulare complex pulmonary disease patients].
    Kuwabara K, Tsuchiya T.
    Nihon Kokyuki Gakkai Zasshi; 2007 Aug; 45(8):587-92. PubMed ID: 17763685
    [Abstract] [Full Text] [Related]

  • 2. [Relations between clinical subtypes of Mycobacterium avium pulmonary disease and polyclonal infections detected by IS1245 based restriction fragment length polymorphism analysis].
    Kuwabara K, Watanabe Y, Wada K, Tsuchiya T.
    Kekkaku; 2004 Feb; 79(2):39-46. PubMed ID: 15031998
    [Abstract] [Full Text] [Related]

  • 3. [Genetic research about Mycobacterium avium complex].
    Ogawa K.
    Kekkaku; 2011 Feb; 86(2):61-8. PubMed ID: 21404652
    [Abstract] [Full Text] [Related]

  • 4. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
    Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M.
    J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
    [Abstract] [Full Text] [Related]

  • 5. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
    Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, Nelson K, Caccitolo J, Alvarez J, Shepherd S, Wilson R, Graviss EA, Wallace RJ.
    Am J Respir Crit Care Med; 2006 Oct 15; 174(8):928-34. PubMed ID: 16858014
    [Abstract] [Full Text] [Related]

  • 6. [Non-tuberculous mycobacteriosis. What has been coming out].
    Kajiki A.
    Kekkaku; 2011 Feb 15; 86(2):113-25. PubMed ID: 21404655
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study.
    Hosono Y, Kitada S, Yano Y, Mori M, Miki K, Miki M, Yoshimura K, Kagawa H, Oshitani Y, Yokota S.
    J Infect Chemother; 2018 May 15; 24(5):353-357. PubMed ID: 29361415
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Difference in drug susceptibility distribution and clinical characteristics between Mycobacterium avium and Mycobacterium intracellulare lung diseases in Shanghai, China.
    Wang W, Yang J, Wu X, Wan B, Wang H, Yu F, Guo Y.
    J Med Microbiol; 2021 May 15; 70(5):. PubMed ID: 33999797
    [Abstract] [Full Text] [Related]

  • 12. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
    Kadota T, Matsui H, Hirose T, Suzuki J, Saito M, Akaba T, Kobayashi K, Akashi S, Kawashima M, Tamura A, Nagai H, Akagawa S, Kobayashi N, Ohta K.
    BMC Infect Dis; 2016 Jan 27; 16():31. PubMed ID: 26818764
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.
    Koh WJ, Jeong BH, Jeon K, Lee SY, Shin SJ.
    Am J Respir Crit Care Med; 2012 Oct 15; 186(8):797-802. PubMed ID: 22878282
    [Abstract] [Full Text] [Related]

  • 14. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
    Ogawa K, Sano C.
    Kekkaku; 2013 Mar 15; 88(3):355-71. PubMed ID: 23672176
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
    Zhao X, Wang Y, Pang Y.
    Infect Genet Evol; 2014 Oct 15; 27():332-8. PubMed ID: 25131955
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Outcome of pulmonary Mycobacterium avium complex (MAC) disease treated with clarithromycin (CAM)-containing regimens].
    Shirai M, Hayakawa H, Nakano Y, Kuroishi S, Nakano Y, Todate A, Suda T, Chida K.
    Nihon Kokyuki Gakkai Zasshi; 2004 Oct 15; 42(10):875-9. PubMed ID: 15566000
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease.
    Hasegawa N, Nishimura T, Ohtani S, Takeshita K, Fukunaga K, Tasaka S, Urano T, Ishii K, Miyairi M, Ishizaka A.
    Chest; 2009 Dec 15; 136(6):1569-1575. PubMed ID: 19542259
    [Abstract] [Full Text] [Related]

  • 20. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
    Ye JJ, Wu TS, Chiang PC, Lee MH.
    J Microbiol Immunol Infect; 2007 Aug 15; 40(4):342-8. PubMed ID: 17712469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.